Article
Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.
BMC medicine - 8 Oct 2024
Han Ji-Youn, Ahn Myung-Ju, Lee Ki Hyeong, Lee Yun-Gyoo, Kim Dong-Wan, Min Young Joo, Kim Sang-We, Cho Eun Kyung, Kim Joo-Hang, Lee Gyeong-Won, Lee Sung Sook, Lee Na Mi, Jang Hyun Woo, Han Heewon, Park Hyejoo, Lee Jieon, Cho Byoung Chul
Abstract excerpt
BACKGROUND: Lazertinib is a potent, irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with significant efficacy in patients with EGFR T790M-mutated non-small cell lung cancer (NSCLC). This is the final overall survival (OS) report from the phase 1/2 LASER201 study in patients with advanced NSCLC with disease progression on or after prior EGFR TKI therapy....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.